

**ASCO/FDA**  
**JOINT LUNG CANCER PANEL**  
**2002-2003**

---

**Paul Bunn, MD (NCE-Chair)**

University of Colorado Cancer Center  
Denver, CO

**Laurie Burke (NCE)**

Office of New Drugs, CDER/FDA  
Rockville, MD

**Renzo Canetta, MD (CE)**

Bristol-Myers Squibb Pharmaceutical  
Research Institute  
Wallingford, CT

**Martin H. Cohen, MD (CE)**

Food and Drug Administration  
Rockville, MD

**Janet Dancey (NCE)**

CTEP/DCTD National Cancer Institute  
Bethesda, MD

**Thomas R. Fleming, PhD (NCE)**

University of Washington  
Department of Biostatistics  
Seattle, WA

**Richard J. Gralla, MD (NCE)**

New York Lung Cancer Alliance  
New York, NY

**David Johnson, MD (CE-Chair)**

Division of Medical Oncology  
Vanderbilt University Medical School  
Nashville, TN

**Richard Kaplan, MD (CE)**

National Cancer Institute  
Bethesda, MD

**Patricia Keegan, MD (NCE)**

DCTDA, CBER, FDA  
Rockville, MD

**Gerard T. Kennealey, MD (NCE)**

Astra Zeneca Pharmaceuticals  
Wilmington, DE

**Minesh P. Mehta, MD (CE)**

*ASTRO Liaison*  
University of Wisconsin Hospital  
Medical School  
Department of Human Oncology  
Madison, WI

**Richard Pazdur, MD (CE)**

Division of Oncology Drug Products  
U.S. Food and Drug Administration  
Rockville, MD

**Steve Piantadosi, MD, PhD (CE)**

Johns Hopkins Kimmel Cancer Center  
Baltimore, MD

**Sheila Ross (CE)**

*ALCASE Liaison*  
Annapolis, MD

**Scott Saxman (CE)**

National Cancer Institute  
Rockville, MD

**Ellen Stovall (NCE)**

National Coalition for Cancer Survivorship  
Silver Spring, MD

**Grant Williams, MD (NCE/CE-Co-Chair)**

Food and Drug Administration/CDER  
Division of Oncology Drug Products  
Rockville, MD

CE-Classical Endpoints  
NCE-Non-classical Endpoints